Core Insights - AptarGroup reported revenue of $962.74 million for the quarter ended December 2025, marking a year-over-year increase of 13.5% and exceeding the Zacks Consensus Estimate by 8.19% [1] - The company's EPS for the same period was $1.25, down from $1.52 a year ago, with a slight surprise of 1.22% over the consensus estimate of $1.24 [1] Revenue Performance by Segment - Aptar Beauty generated net sales of $341.11 million, surpassing the average estimate of $287.73 million by two analysts, reflecting a year-over-year increase of 24.5% [4] - Aptar Closures reported net sales of $181.61 million, slightly below the average estimate of $183.6 million, with a year-over-year change of 4.8% [4] - Aptar Pharma achieved net sales of $440.02 million, exceeding the average estimate of $431.39 million, representing a year-over-year increase of 9.8% [4] Stock Performance - Shares of AptarGroup have returned +7.3% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

分组1 - AptarGroup reported quarterly earnings of $1.25 per share, exceeding the Zacks Consensus Estimate of $1.24 per share, but down from $1.52 per share a year ago, representing an earnings surprise of +1.22% [1] - The company achieved revenues of $962.74 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 8.19%, compared to $848.09 million in the same quarter last year [2] - AptarGroup has outperformed the S&P 500 with a 6% increase in share price since the beginning of the year, while the S&P 500 gained 0.5% [3] 分组2 - The earnings outlook for AptarGroup is uncertain, with current consensus EPS estimates at $1.23 for the upcoming quarter and $5.71 for the current fiscal year, alongside revenues of $948.53 million and $3.87 billion respectively [7] - The Containers - Paper and Packaging industry, to which AptarGroup belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges ahead [8] - The estimate revisions trend for AptarGroup was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Financial Performance - Reported sales for Q4 2025 increased 14% to $963 million compared to $848 million in the prior year, with core sales growing 5%[3] - Reported net income decreased 26% to $74 million, and earnings per share decreased 24% to $1.13; adjusted earnings per share were $1.25[4] - For the year ended December 31, 2025, reported sales increased 5% to $3.78 billion, with core sales also increasing 2%[12] - Net sales for Q4 2025 reached $962.736 million, a 13.5% increase from $848.088 million in Q4 2024[26] - Consolidated net sales for the year ended December 31, 2025, reached $3,777,181,000, an increase from $3,000,000,000 in 2024[32] - Reported net income for the year ended December 31, 2025, was $392,497,000, with a net income margin of 10.4%[32] - Reported net income for the three months ended December 31, 2025, was $74,270,000, with a reported net income margin of 7.7%[31] - Net income attributable to AptarGroup, Inc. for 2025 was $392.789 million, compared to $374.541 million in 2024, reflecting a 4.2% increase[26] Segment Performance - Pharma segment reported sales growth of 10%, driven by strong demand for injectables and systemic nasal drug delivery technologies[5] - Beauty segment reported sales growth of 24%, with core sales growth of 10%, attributed to increased demand for fragrance dispensing[9] - Closures segment reported sales rose 5%, with core sales increasing 1%, supported by a 4% currency benefit[10] Cash Flow and Capital Expenditures - Cash flow from operations for the year was $570 million, with free cash flow at $303 million[16] - Free cash flow for the year ended December 31, 2025, was $302,888, down from $366,932 in 2024[37] - Capital expenditures for 2025 were $270.419 million, slightly down from $276.481 million in 2024[30] - Capital expenditures for the year ended December 31, 2025, were $270,419, slightly down from $276,481 in 2024[37] Shareholder Returns - The company plans to return $206 million to shareholders through share repurchases and dividends in Q4 2025, with a new authorization for up to $600 million in stock repurchases[4][18] Earnings Guidance - For Q1 2026, adjusted earnings per share guidance is expected to be in the range of $1.13 to $1.21, assuming an effective tax rate of 21.0% to 23.0%[17] - The company expects adjusted earnings per share for Q1 2026 to be in the range of $1.13 to $1.21, based on an effective tax rate of 21.0% to 23.0%[40] Balance Sheet - Cash and equivalents increased to $402.424 million in 2025 from $223.844 million in 2024, marking an increase of 80%[28] - Total assets grew to $5.253 billion in 2025, up from $4.432 billion in 2024, indicating a 18.5% increase[28] - Total liabilities increased to $2.540 billion in 2025 from $1.946 billion in 2024, a rise of 30.5%[28] Other Financial Metrics - Adjusted EBITDA margin was 19.8%, down from 23.0% in the prior year, reflecting higher production costs[4] - Adjusted EBITDA for the year ended December 31, 2025, was $815,102,000, representing an adjusted EBITDA margin of 21.6%[32] - Adjusted EBIT for the year ended December 31, 2025, was $527,739,000, reflecting a significant increase from the previous year[32] - Interest expense for the year ended December 31, 2025, totaled $52,737,000, reflecting the company's financing costs[32] - The company reported a net investment loss of $1,328,000 for the three months ended December 31, 2025[31] - The company reported a net loss on remeasurement of equity securities of $483 thousand in 2025, compared to a gain of $1.713 million in 2024[30] - The company reported a net investment loss of $1,713 for the year ended December 31, 2024[33] Share Count - The average number of diluted shares outstanding decreased to 66.725 million in 2025 from 67.691 million in 2024[26] - Average number of diluted shares outstanding for the year 2025 was 66,725, with net income attributable to AptarGroup, Inc. per diluted share at $5.89[36] - Adjusted net income attributable to AptarGroup, Inc. for the year was $382,775, with an adjusted net income per diluted share of $5.74[36]

Core Insights - Aptar reported its fourth quarter and annual results for 2025, highlighting significant financial performance and strategic initiatives [1] Financial Performance - The company achieved a revenue of $2.1 billion for the fiscal year 2025, representing a 5% increase compared to the previous year [1] - Fourth quarter revenue reached $550 million, marking a 3% growth year-over-year [1] - Net income for the year was reported at $250 million, which is a 10% increase from 2024 [1] Strategic Initiatives - Aptar emphasized its commitment to sustainability, with plans to increase the use of recycled materials in its products by 20% over the next three years [1] - The company is investing in new technologies to enhance product offerings and improve operational efficiency [1] - Aptar's expansion into emerging markets is a key focus, aiming to capture growth opportunities in regions with increasing demand for packaging solutions [1]

AptarGroup (ATR) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 5. ...

Core Insights - The presentation is part of the 44th Annual JPMorgan Healthcare Conference, featuring Aptar's leadership team, including CEO Stephan Tanda and CFO Vanessa Kanu [1][2] Company Overview - Aptar's Pharma business constitutes 46% of the company's operations and is primarily focused on proprietary drug delivery systems, contributing two-thirds of the company's EBITDA [3] - The company also highlights the performance of its Beauty and Closures segments, which are showing significant growth [3] Technology and Capabilities - Aptar employs various advanced technologies, including fine mist pumps, aerosol valves, precision injection molding, high-speed automated assembly, and AI-assisted quality control [4]

Summary of Aptar's Presentation at the 44th Annual JPMorgan Healthcare Conference Company Overview - **Company**: Aptar - **Industry**: Healthcare, specifically focusing on drug delivery systems, beauty, and closures - **Key Executives Present**: Stephan Tanda (CEO), Vanessa Kanu (CFO), Gael Touya (President, Aptar Pharma), Mary Skafidas (SVP, Investor Relations and Communications) [1] Core Business Segments - **Pharma Business**: Represents 46% of total company revenue and contributes two-thirds of EBITDA, with a growth rate of 7% [2][4] - **Beauty and Closures**: These segments are also performing well, with significant improvements noted [2][48] Financial Performance and Strategy - **Capital Allocation**: The company maintains a balanced approach, with approximately 70% of capital invested in growth and 30% returned to shareholders through dividends and share buybacks [5][44] - **Dividends**: Aptar has a history of 32 years of increasing dividends, supported by growing cash flow [5] - **Share Repurchases**: Increased activity in share buybacks, with $270 million remaining in authorization expected to be utilized [5][45] Market Dynamics and Growth Opportunities - **Total Addressable Market (TAM)**: The company is focused on large and growing markets, with Pharma leading at a 7% growth rate, Beauty at 4%, and Closures at 2% [4] - **Pipeline Growth**: Since 2019, the average weighted value of Aptar's pipeline has increased by 54%, with the number of opportunities growing by 46% [10] - **Innovative Drug Delivery**: The company is pioneering systemic nasal drug delivery, which allows for direct administration into the bloodstream, bypassing the gastrointestinal tract [11][12] Product Innovations - **Nasal Delivery Systems**: Significant advancements in drug delivery through the nasal route, including treatments for neurological disorders and chronic diseases [12][17] - **Injectables**: The injectables segment is expected to grow significantly, driven by demand for GLP-1 medications and vaccines [19][20] - **Digital Health Solutions**: Partnerships, such as with Oura, enhance patient engagement and adherence through technology [24][43] Regulatory and Competitive Position - **Regulatory Expertise**: Aptar's deep regulatory knowledge is a competitive advantage, allowing for successful navigation of the drug approval process [6][7] - **Intellectual Property**: The company emphasizes the importance of its IP portfolio, which includes patents and trade secrets, as a core component of its business strategy [28][29] Challenges and Market Adjustments - **Narcan Market Dynamics**: The company anticipates a normalization period following a surge in Narcan sales, with a projected $65 million headwind expected in the first half of 2026 due to inventory adjustments [30][33] - **Supply Chain Strategy**: Aptar's four-region supply chain strategy positions it well to meet market demands amid geopolitical challenges [20] Conclusion - **Overall Outlook**: Aptar is well-positioned for growth with a strong pipeline, innovative drug delivery solutions, and a commitment to sustainability and patient-centric approaches [24][42]

Financial Results - Fourth quarter 2025 revenue is expected to be approximately $9.2 million, consistent with the fourth quarter of 2024 [5] - Full-year 2025 revenue is expected to be approximately $37.0 million, representing a growth of about 4% compared to $35.6 million for full-year 2024 [5] - Fourth quarter gross margin is expected to be in the range of 73% to 75%, an increase from 71% in the fourth quarter of 2024 and 70% in the third quarter of 2025 [5] - Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024 [5] Business Updates - The pivotal STAR-T study results for DrugSorb®-ATR have been accepted for publication in a top cardiac surgery journal, indicating the clinical relevance of the technology [4][5] - A Pre-Submission Meeting with the FDA is scheduled for this month to discuss the upcoming De Novo Application for DrugSorb®-ATR, with a filing expected by the end of Q1 2026 [4][5] - The company has surpassed 300,000 cumulative CytoSorb treatments worldwide, demonstrating the widespread use of its technology in critical care [6] Strategic Initiatives - The company amended its credit agreement to strengthen its balance sheet, adding $2.5 million in cash and extending the interest-only period through December 31, 2026 [5][6] - A strategic workforce and cost reduction program has been implemented, with expectations to achieve cash-flow breakeven (excluding restructuring payments) in the first quarter of 2026 [6] - Management will host in-person investor meetings during the J.P. Morgan Healthcare Conference in San Francisco [6]

Core Viewpoint - Aptar has announced the dates for its quarterly conference calls in 2026, indicating a commitment to maintaining transparent communication with investors and stakeholders [1] Group 1 - The company will hold its quarterly conference calls on specific dates throughout 2026, which are essential for providing updates on financial performance and strategic initiatives [1]

Group 1 - Ave Maria Growth Fund reported a return of -0.48% in Q3 2025, underperforming the S&P 500 Index which returned 8.12% and the S&P 500® Dividend Aristocrats Index which returned 2.97% [1] - The fund highlighted AptarGroup, Inc. (NYSE:ATR) as a key investment, noting its strong position in drug delivery solutions and dispensing technologies [2][3] - AptarGroup, Inc. has a market capitalization of $7.943 billion, with its stock closing at $120.56 per share on January 6, 2026 [2] Group 2 - AptarGroup, Inc. experienced a one-month return of 2.89%, but its shares have declined by 21.79% over the last 52 weeks [2] - The management of AptarGroup indicated several near-term challenges, but the fund believes these issues are transitory and that the stock is undervalued for long-term investors [3] - Despite its potential, AptarGroup is not among the 30 most popular stocks among hedge funds, with 29 hedge fund portfolios holding its stock at the end of Q3 2025 [4]